Abstract
Human papillomavirus (HPV) is increasingly identified as a causative agent for oropharyngeal squamous cell carcinoma (OPSCC), often in relatively young patients lacking traditional carcinogenic risk factors such as tobacco and alcohol use. A growing body of literature has highlighted the importance of immune impairment in the pathogenesis of HPV-related premalignant and malignant lesions in the uterine cervix and, more recently, the oropharynx. This chapter will summarize current knowledge of the mechanisms that human papillomaviruses have evolved to evade the host immune system in the development of malignancy and will conclude with a discussion on preventive and therapeutic strategies that exploit these immune modulatory mechanisms.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Albers A, Abe K, Hunt J et al (2005) Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65:11146–11154
Alcocer-Gonzalez JM, Berumen J, Taméz-Guerra R et al (2006) In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 19:481–491
Allen C, Lewis J, El-Mofty S et al (2010) Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 120:1756–1772
Allen C, Judd N, Bui J et al (2011) The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 122:144–157
Badoual C, Hans S, Merillon N et al (2013) PD-1-expressing tumor infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73:128–138
Bauman JE, Gooding WE, Clump DA et al (2014) Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC). Abstracts from the annual meeting of the American Society of Clinical Oncology, Chicago, Illinois, 31 May–3 June, 2014
Beachler DC, Weber KM, Margolick JB et al (2012) Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev 21:122–133
Best S, Niparko K, Pai S (2012) Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers. Otolaryngol Clin N Am 45:807–822
Bhat P, Mattarollo SR, Gosmann C et al (2011) Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev 239:85–98
Bodily J, Laimins LA (2011) Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol 19:33–39
Brun JL, Dalstein V, Leveque J et al (2011) Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 204:169.e1–8
Chang YE, Laimins LA (2000) Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 74:4174–4182
Clinical Trials Database (2014) National Cancer Institute, Bethesda. http://www.cancer.gov/clinicaltrials/search/view?cdrid=749477&version=HealthProfessional. Accessed 26 June 2014
Denny LA, Franceschi S, de Sanjosé S et al (2012) Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 30S:F168–F174
Duray A, Demoulin S, Hubert P et al (2010) Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010:701657
El-Omar EM, Ng MT, Hold GL (2008) Polymorphisms in toll-like receptor genes and risk of cancer. Oncogene 27:244–252
Ferris R (2013) PD-1 targeting in cancer immunotherapy. Cancer 119. doi:10.1002/cncr.27832
Frazer IH (2009) Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 384:410–414
Gildener-Leapman N, Lee J, Ferris RL (2013) Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncol. doi:10.1038/bjc.2013.645
Giuliano AR, Palefsky JM, Goldstone S et al (2011) Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364:401–411
Kanodia S, Fahey LM, Kast WM (2007) Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 7:79–89
King EV, Ottensmeier CH, Thomas GJ (2014) The immune response in HPV+ oropharyngeal cancer. Oncoimmunol 3:e27254
Koskinen WJ, Partanen J, Vaheri A et al (2006) HLA-DRB1, -DQB1 alleles in head and neck carcinoma patients. Tissue Antigens 67:237–240
Lyford-Pike S, Peng S, Young G et al (2013) Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 73:1733–1741
Madkan VK, Cook-Norris RH, Steadman MC et al (2007) The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental factors. Br J Dermatol 157:228–241
Malejczyk J, Malejczyk M, Majewski S et al (1994) Increased tumorigenicity of human keratinocytes harboring human papillomavirus type 16 is associated with resistance to endogenous tumor necrosis factor-alpha-mediated growth limitation. Int J Cancer 56:593–598
Malm IJ, Bruno TC, Fu J et al (2014) Expression profile and in vitro blockade of PD-1 in HPV-negative head and neck squamous cell carcinoma. Head Neck. doi:10.1002/hed.23706
Näsman A, Romanitan M, Nordfors C et al (2012) Tumor Infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS ONE 7:e38711
Nees M, Geoghegan JM, Hyman T et al (2001) Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kB-responsive genes in cervical keratinocytes. J Virol 75:4283–4296
O’Brien PM, Campo MS (2002) Evasion of host immunity directed by human papillomavirus-encoded proteins. Virus Res 88:103–117
Pai S (2013) Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. Oncoimmunol 2:e24065
Quezada S, Peggs K (2013) Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer 108:1560–1565
Schiller JT, Castellsagué X, Garland SM (2012) A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30S:F123–F138
Scott M, Nakagawa M, Moscicki A (2001) Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 8:209–220
Sewell DA, Pan ZK, Paterson Y (2008) Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 26:5315–5320
Sin JI, Kim JM, Bae SH et al (2009) Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin-/granzyme-mediated pathway. Mol Ther 17:906–913
Spanos WC, Nowicki P, Lee DW et al (2009) Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 135:1137–1146
Stanley MA, Pett MR, Coleman N (2007) HPV: from infection to cancer. Biochem Soc Trans 35:1456–1460
Stanley MA (2008) Immunobiology of HPV and HPV vaccines. Gyn Oncol 109:S15–S21
Stanley MA, Pinto LA, Trimble C (2012) Human papillomavirus vaccines—immune response. Vaccine 30S:F83–F87
Tindle RW (2002) Immune evasion in human papillomavirus-associated cervical cancer. Cancer 2:1–7
Vambutas A, DeVoti J, Pinn W et al (2001) Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol 101:94–99
Vu HL, Sikora AG, Fu S et al (2010) HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett 288:149–155
Zhou Q, Zhu K, Cheng H (2011) Ubiquitination in host immune responses to human papillomavirus infection. Arch Dermatol Res 303:217–230
Zhou Q, Zhu K, Cheng H (2013) Toll-like receptors in human papillomavirus infection. Arch Immunol Ther Exp 61:203–215
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Schmitt, N.C., Ferris, R.L., Kim, S. (2015). The Role of Immune Modulation in the Carcinogenesis and Treatment of HPV-Associated Oropharyngeal Cancer. In: Miller, D., Stack, M. (eds) Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-21100-8_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-21100-8_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-21099-5
Online ISBN: 978-3-319-21100-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)